OUR RESEARCH FOCUS
August 13, 2018
FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans
WAYNE, Pa.--(BUSINESS WIRE)—Onspira Therapeutics, a privately-held clinical-stage biopharmaceutical company dedicated to developing therapies to treat rare
July 05, 2017
Malvern biopharm firm targeting rare pulmonary disorders raises $1M
The company is the latest to be launched by Malvern-based NeXeption.